Kristen Landon
About Kristen Landon
Chief Commercial Officer at 60 Degrees Pharmaceuticals (SXTP); joined in February 2024 (employment term began February 12, 2024), bringing over 26 years of commercial leadership in pharma across TherapeuticsMD, Radius Health, Sprout Pharmaceuticals, Actavis, Forest Labs, Abbott, and Novartis; MBA from Silberman College of Business at Fairleigh Dickinson University and a Bachelor’s degree from Kean University . Company performance context: FY 2024 revenue was $681,345* versus $253,573 in FY 2023 , and FY 2024 EBITDA was $(9,664,703)* versus $(5,104,264)* in FY 2023 (values marked * retrieved from S&P Global). Vesting of her equity occurs annually on the last day of each fiscal year, creating predictable windows where insider selling pressure could arise .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| TherapeuticsMD | Senior Vice President, Marketing & Communications | Not disclosed | Led branded portfolio, insights, and corp comms; launched/relaunched >12 brands, many with peak revenues >$100M |
| Radius Health | Vice President, Marketing | Not disclosed | Commercial leadership across women’s health and other categories |
| Sprout Pharmaceuticals (acquired by Valeant) | Vice President, Marketing | Not disclosed | Commercial leadership; brand launch/scale experience |
| Actavis Plc | Executive Director, Women’s Health | Not disclosed | Women’s health portfolio leadership |
| Forest Labs; Abbott Labs; Novartis | Sales & Marketing roles | Not disclosed | Increasing responsibility in sales and marketing across large-cap pharma |
External Roles
No public company directorships or external board roles disclosed for Landon in SXTP filings .
Fixed Compensation
| Metric (USD) | FY 2024 |
|---|---|
| Base Salary | $300,000 |
| Cash Bonus (actual paid) | $113,570 |
| Stock Bonus | $38,125 |
| Option Award (grant-date fair value) | $19,167 |
| Total Compensation | $470,862 |
- Employment agreement provides an annual base salary of $300,000 and eligibility for sales/performance bonuses and standard senior executive benefits; employment is at will (either party can terminate at any time) .
Performance Compensation
Equity Awards
| Award | Grant date | Shares/Options | Exercise price | Term/Expiry | Vesting schedule | Notes |
|---|---|---|---|---|---|---|
| Non-qualified stock options | Sept 26, 2024 | 4,167 options | $6.85 per share | Expires Sept 26, 2034 | Vests annually in 5 equal tranches on last day of each fiscal year; first vest Dec 31, 2024 | Cashless exercise provision noted in agreement |
- Outstanding and exercisable at Dec 31, 2024: 834 options exercisable; 3,333 unearned/unexercised under equity incentive plan .
Annual Incentive (2024)
| Metric | Weighting | Target | Actual | Payout ($) | Vesting |
|---|---|---|---|---|---|
| Sales/performance bonuses | Not disclosed | Not disclosed | Not disclosed | $113,570 | N/A |
- No specific quantitative performance metrics (revenue growth, EBITDA, TSR) tied to Landon’s incentives are disclosed in filings; bonuses are paid “to the extent certain events occur or if applicable performance goals are met” .
Equity Ownership & Alignment
| Holder | Shares beneficially owned | Percent of class | As-of date |
|---|---|---|---|
| Kristen Landon | 5,374 | <1% | Record date August 14, 2025 |
| Options status (Dec 31, 2024) | Exercisable (#) | Unexercised unearned (#) | Exercise price | Expiration |
|---|---|---|---|---|
| Landon options | 834 | 3,333 | $6.85 | Sept 26, 2034 |
- Shares pledged as collateral: not disclosed for Landon; company policy prohibits hedging and discourages pledging, requiring pre-approval and demonstration of repayment capacity; short sales and publicly-traded options are prohibited .
- Stock ownership guidelines (e.g., multiple of salary): not disclosed in filings reviewed .
- Section 16 compliance: filings note Landon failed to file timely Form 4s for option grants dated Sept 26, 2024 and Jan 17, 2025 .
Employment Terms
| Term | Details |
|---|---|
| Employment start | Term began February 12, 2024 |
| Employment type | At-will for both parties |
| Base salary | $300,000 per year |
| Bonus eligibility | Sales/performance bonuses as events occur or goals are met |
| Equity | Five-year option for 4,167 shares; cashless exercise provision; board set exercise price at $6.85 on Sept 26, 2024 after shareholder approval of plan share increase |
| Severance | Not disclosed for Landon; at-will nature stated, no severance or change-of-control economics described in Landon’s agreement section |
| Non-compete / Non-solicit | Not disclosed for Landon in filings reviewed |
Company Financial Performance Context
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Revenues (USD) | $253,573 | $681,345* |
| EBITDA (USD) | $(5,104,264)* | $(9,664,703)* |
Values marked * retrieved from S&P Global.
Risk Indicators & Red Flags
- Section 16(a) delinquent reports: filings state Landon failed to file timely Form 4s for options issued on Sept 26, 2024 and Jan 17, 2025 .
- Clawback policy: Board adopted an executive compensation recoupment policy on Nov 23, 2023 consistent with SEC Rule 10D‑1 and Nasdaq listing standards; applies to all corporate officers and performance-based awards in case of restatements or misconduct .
- Hedging/pledging: Insider Trading Policy prohibits hedging and short sales, discourages pledging without pre-approval; additional procedures include pre-clearance for designated insiders .
- Transparency risk: Specific quantitative performance metrics tied to Landon’s incentive payouts are not disclosed (only generic references to goals/events) .
- Equity award liquidity windows: Annual vesting on the last day of each fiscal year (first vest 12/31/2024) creates predictable windows for potential insider selling pressure .
Investment Implications
- Alignment: Landon’s equity is entirely option-based with a five-year annual vest; combined with a clawback and strict hedging/pledging restrictions, this structure supports long-term alignment and reduces hedging risk .
- Retention risk: At-will employment with no disclosed severance or change-of-control protections for Landon may limit retention incentives relative to typical pharma CCO packages; multi-year option vesting provides a counterbalance .
- Trading signals: Annual vesting on fiscal year-end could lead to recurring windows of potential insider selling or 10b5‑1 planning; monitor Section 16 filings around year-end given prior delinquency noted by the company .
- Execution: Deep commercial background across multiple therapeutic areas and >12 brand launches suggest capability to drive commercialization; investors should weigh this against the company’s small revenue base and widening EBITDA losses in FY 2024* . Values marked * retrieved from S&P Global.